An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Generalized Epidermolysis Bullosa Simplex
Interventions
- DRUG: AC-203
- DRUG: Vehicle
Sponsor
TWi Biotechnology, Inc.